Compare ARK Genomic Revolution ETF (ARKG) vs Check Point Software Technologies Ltd (CHKP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Check Point Software Technologies Ltd — how do they compare? ARK Genomic Revolution ETF trades at $40.83, while Check Point Software Technologies Ltd trades at $131.7 (market cap $13.70B). The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, Check Point Software Technologies Ltd nearer its low. Which is the better fit depends on your goals.
| ARKG | CHKP | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $43.57 | $223.00 |
52-Week Low | $23.09 | $112.47 |
Market Cap | — | $13.70B |
Enterprise Value | — | $12.91B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Check Point Software (CHKP) trades at $131.70, down 4.68% today, amid a mixed technical picture with a bullish moving average signal but overbought RSI readings. The company maintains strong fundamentals with a 38.37% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights strategic AI partnerships with OpenAI and AWS, positioning it for growth in cybersecurity.
The outlook is cautiously optimistic with a consensus price target of $148.73 offering 13% upside. Risks include competitive pressures and a potential slowdown in software spending. Analyst sentiment is balanced with 46% buy ratings, though insider selling and an ongoing legal investigation warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Check Point Software Technologies Ltd
Check Point is a global leader in cybersecurity solutions. It provides comprehensive protection against advanced cyber threats for corporate networks, cloud environments, mobile devices, and critical infrastructure.
Read more on CHKP →
